相关临床试验
34
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
14.7%
已完成
29
85.3%
暂无批准数据
- Adocia will host a virtual Key Opinion Leader event on June 16, 2026, to present Phase 3 clinical trial results for BioChaperone Lispro in type 2 diabetes. - Dr. Tim Heise, co-founder of Profil Research Institute, will present the data alongside Adocia's CEO Olivier Soula and Head of R&D You-Ping Chan. - BioChaperone Lispro is an ultra-rapid prandial insulin combining Adocia's BioChaperone technology with insulin lispro, designed to reduce post-meal hyperglycemia and minimize hypoglycemia risk. - The product was licensed to Tonghua Dongbao in 2018 for development and commercialization in China and other Asian countries.
- Adocia has filed a patent for its AdoXLong platform, a new long-acting peptide technology that could extend treatment duration to at least one month for diabetes and obesity therapies. - The platform uses biocompatible polymers chemically linked to peptides without altering their mechanisms of action, with early semaglutide results showing promise for once-monthly injections. - The technology is designed to work with various peptides including GLP-1, GIP, amylin and dual/triple agonists, potentially improving treatment persistence while reducing manufacturing capacity requirements. - Adocia continues advancing its BioChaperone platform with two ongoing feasibility studies in collaboration with undisclosed large pharmaceutical companies for obesity treatments.
- BioChaperone Lispro (THDB0206) demonstrated non-inferior HbA1c reduction compared to Humalog in a Phase 3 trial of 1,040 Chinese adults with Type 2 diabetes. - The ultra-rapid insulin formulation showed statistically significant reduction in post-meal blood glucose rise and improved daily glucose control versus standard care. - The trial results support Adocia's partnership with Tonghua Dongbao and advance the innovative insulin toward potential regulatory approval in China.
- Adocia successfully completed a €9.7 million private placement through issuing 2.125 million new shares with attached warrants, extending the company's cash runway to Q2 2026. - The funding will support development of the AdoShell® Islets project with 50% of proceeds allocated to toxicology studies and clinical batch preparation for first-in-human trials. - Key investors include Armistice Capital (€7 million), company chairman Gerard Soula (€0.5 million), and historical investor Vester Finance (€0.9 million). - The company's diabetes and obesity-focused pipeline includes four proprietary technology platforms: BioChaperone®, AdOral®, AdoShell®, and AdoGel®.
- A novel hydrogel formulation of semaglutide allows for a slow, steady release of the drug over one month, potentially reducing the frequency of injections. - Preclinical studies in rats demonstrated that the semaglutide-laden hydrogel achieved a consistent drug release profile over one month with no signs of inflammation. - Clinical trials in humans are anticipated within the next few years, pending successful testing in pigs, whose skin and endocrine systems are similar to humans. - This new formulation could improve patient adherence to semaglutide regimens for both type 2 diabetes and weight loss, enhancing treatment outcomes.
